Predicting Response to Biochemotherapy in Melanoma
Author Information
Author(s): Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L
Primary Institution: University Hospital, Linköping
Hypothesis
Can the presence of tumour-infiltrating CD4+ lymphocytes predict the therapeutic effect of biochemotherapy in metastatic malignant melanoma?
Conclusion
The presence of CD4+ lymphocytes in melanoma metastases is significantly correlated with better treatment responses and longer survival times in patients undergoing biochemotherapy.
Supporting Evidence
- A statistically significant correlation was found between the occurrence of CD4+ lymphocytes and tumour regression during biochemotherapy.
- 12 out of 14 patients with moderate to high numbers of infiltrating CD4+ lymphocytes achieved tumour regression.
- Patients with moderate to high numbers of CD4+ lymphocytes had significantly longer time to progression and overall survival compared to those with low numbers.
Takeaway
Doctors can look for certain immune cells in melanoma patients to see if they are likely to benefit from a specific cancer treatment.
Methodology
The study analyzed fine-needle aspirates from melanoma metastases to identify CD4+ lymphocytes and correlated their presence with treatment outcomes.
Participant Demographics
25 patients with systemic and 16 with regional metastatic melanoma
Statistical Information
P-Value
P = 0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website